explore -WSS

explore

author：focus 2025-08-12 11:28:29 - browse：1

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Amazon expands telehealth clinic nationwide

knowledge

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

BIO selects John Crowley as new CEO

FDA investigates CAR

FDA investigates CAR

Mitch McConnell episode has important public health takeaway

Amazon expands telehealth clinic nationwide

hotspot

explore

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

BIO selects John Crowley as new CEO

George Santos makes 1st court appearance after pleading not guilty to 13 counts

J&J to emphasize cancer drugs, stop much of its vaccine research

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The high personal cost of affirmative action for Black doctors

State Dept. review finds Biden bears some blame for Afghanistan failures

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

focus

CDC director unscathed in first congressional testimony

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

The EPA's new lead rule: How one expert crunched the numbers

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

Wikipedia

knowledge

leisure time